Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome

Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome

The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and to discover characteristics that predict pembrolizumab respo...

Full description

Saved in:
Bibliographic Details
Main Authors: Tianying Su, George E. Duran, Alexa C. Kwang, Nirasha Ramchurren, Steven P. Fling, Youn H. Kim, Michael S. Khodadoust
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
PD-1
Sezary syndrome
single cell RNA-sequencing
intratumoral heterogeneity
immune checkpoint inhibition
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2115197
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2115197

Similar Items